191 related articles for article (PubMed ID: 37743642)
1. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
3. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
4. RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression.
Jiang T; He X; Zhao Z; Zhang X; Wang T; Jia L
FASEB J; 2022 Nov; 36(11):e22618. PubMed ID: 36250924
[TBL] [Abstract][Full Text] [Related]
5. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract][Full Text] [Related]
6. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma.
Du M; Peng Y; Li Y; Sun W; Zhu H; Wu J; Zong D; Wu L; He X
Cell Death Discov; 2022 Feb; 8(1):53. PubMed ID: 35136045
[TBL] [Abstract][Full Text] [Related]
7. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer.
Zhou S; Sheng L; Zhang L; Zhang J; Wang L
Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130542. PubMed ID: 38103759
[TBL] [Abstract][Full Text] [Related]
8. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract][Full Text] [Related]
9. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
10. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
[TBL] [Abstract][Full Text] [Related]
11. LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m
Yu Y; Deng H; Wang W; Xiao S; Zheng R; Lv L; Wang H; Chen J; Zhang B
Clin Transl Med; 2024 Feb; 14(2):e1583. PubMed ID: 38372449
[TBL] [Abstract][Full Text] [Related]
12. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
[TBL] [Abstract][Full Text] [Related]
13. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
14. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
15. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
Hao W; Chen Z; Tang J; Yang R; Gao WQ; Xu H
J Transl Med; 2023 Nov; 21(1):861. PubMed ID: 38017546
[TBL] [Abstract][Full Text] [Related]
16. IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N
Zhang J; Yang K; Bu J; Yan J; Hu X; Liu K; Gao S; Tang S; Gao L; Chen W
Front Oncol; 2022; 12():1035871. PubMed ID: 36313631
[TBL] [Abstract][Full Text] [Related]
17. IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
Lv L; Wei Q; Zhang J; Dong Y; Shan Z; Chang N; Zhao Y; Bian P; Yi Q
Cell Mol Biol Lett; 2024 Mar; 29(1):39. PubMed ID: 38504159
[TBL] [Abstract][Full Text] [Related]
18. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
19. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization.
Qin J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H; Cai J
Transl Oncol; 2023 Nov; 37():101764. PubMed ID: 37643553
[TBL] [Abstract][Full Text] [Related]
20. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
